Our Values
Innovation, Collaboration, and Hope
Outsmarting cancer, together
Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.
Our Mission
MoST Clinical Trials
MoST SubstudiesRecent News
$185 million investment to fast-track treatments for rare and ‘untreatable’ cancers
The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives. A private public partnership to strengthen Australia’s position at the forefront of the cancer treatment revolution
APOS 2021 - DNA & Beyond - online event
Renowned experts discussing the future of genomic cancer medicine, developing new models for health care, data and machine learning. Join us for 4 sessions over 4 days to explore novel technologies, innovative therapies and a systems approach to managing cancer risk and providing healthcare. November Monday 22nd, Tuesday 23rd, Wednesday 24th and Thursday 25th November 2021; 5pm - 7pm AEST
Pancreatic cancer program
Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.